October 19th, 2016 – Chicago, IL – PancreaCell a Leonhardt Ventures Co. incubating in the Leonhardt’s Launchpads Utah organ regeneration innovation accelerator in Salt Lake City, Utah presented today at the Annual Pancreatic Disorders and Treatment Conference in Chicago, IL – http://pancreas.conferenceseries.com/ its updated design and translational research plan with intention to bring to market the first total pancreas regeneration technology.

The PancreaCell product is a combination device implanted in a patient’s abdomen just below the skin and a proprietary fiteen component stem cell based PC-15 pancreas regeneration composition. It is designed to regenerate a pancreas over a 36 month course of treatment. The device is a bioelectric stimulator the controls expression of over 12 regeneration promoting cytokines combined with a micro infusion pump that has two re-fillable chambers via silcone septums placed just below the skin surface. The programmable micro infusion pump is easily re-filled with a standard syringe and needle at home. The current protocol calls for 2mls of infusion daily of the PC-15 regeneration composition. The stimulator pump is connected to the pancreas via a pacing infusion lead that is affixed to the pancreas with an atraumatic tip. The patented and patent pending bioelectric signal controlled protein expressions include SDF-1, a known stem cell homing signal, IGF-1, HGF, EGF, Activin A+B, eNOS, VEGF, Follistatin, Tropoelastin, TNF A and the team is working on adding GDF-10, GDF-11, BMP-4+7, Serontonin, Neuorgenin 3 as well as other cytokines.

The company shared their translational research plan which starts now with lab testing utilizing the new technology of “organs in a dish” side by side with small animal safety studies. This will be followed by both large animal and donor human pancreas studies. The donor human pancreas will be preserved after harvest with a perfusion system meant to keep the pancreas as “alive” as possible through the testing. The company plan is to follow this with a pilot clinical study focused first on safety with dose escalation in late 2017 or early 2018.

More information may be found on the company’s web site at https://leonhardtventures.com/pancreacell/ This includes an introduction animation video – https://vimeo.com/170533425 and slide deck – https://app.slidebean.com/p/lEWTFzlvCu/PancreaCell as well as scientific articles that support the rational of the components of the PancreaCell protocol and product – https://leonhardtventures.com/pancreacell/#toggle-id-2

PancreaCell: Is a startup licensable technology platform (LTP) founded in early 2015 incubating now within the Leonhardt’s Launchpad’s Utah, Inc. organ regeneration innovation accelerator in Salt Lake City, Utah. The company is focused on pancreas regeneration and pancreatic cancer treatment based on its three part technology platform of bioelectric stimulation + micro infusion pump + fifteen component regeneration composition – https://leonhardtventures.com/pancreacell/

Leonhardt’s Launchpad Utah, Inc.: Formed in late 2015 is an innovation and startup incuabor/accelerator focused on organ regeneration with a distinguished and experienced Utah based board of advisors – https://leonhardtventures.com/leonhardts-launchpads-utah/

Leonhardt Ventures: Formed in 1982 (originally H.J. Leonhardt & Co.) Leonhardt Ventures led the development in the 1980’s of turn key cath labs and CCU’s, predictably compliant cardiovascular balloon catheters and began organ regeneration research utilziing bioelectric energy and stem cells. In 1988 their research team completed the first ever muscle stem cell repair of a damage heart in an animal. In the 1990’s the team developed and patented the world’s leading stent graft for aortic aneurysm repair, an intravascular lung catheter, vibrational energy systems for preventing clot formation and improving gas exchange, the first stem cell delivery catheters, an electro magnetic radiation delivery catheter, one of the first biological pacemakers and the first percutaneous heart valve. In 1999 they launched the first stem cell repair of damaged hearts company. In 2001 they completed the historic first-in-man non-surgical stem cell repair of a human heart in The Netherlands. Since 2001 the team has focused on the development of an organ regeneration platform technology utilizing the combination of bioelectric signal controlled protein expression and micro infusion pump delivery of a proprietary fifteen component regeneration compositions – www.lventuresnestg.wpenginepowered.com